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Effects of vitamin D3 and its chemical 
analogs on the growth of Hodgkin’s lymphoma, 
in vitro
Rajendra Gharbaran1,2*, Bo Zhang2, Luis Valerio1,2, Onyekwere Onwumere2,3, Madeline Wong2, Jason Mighty2,3 
and Stephen Redenti2,3
Abstract 
Objective: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed 
varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. The objective 
of this study was to address the potential effects of VD3 and vitamin D3 analogs (VDAs) on the growth of Hodgkin’s 
lymphoma (HL), a malignant pathology of B cell origin, in vitro.
Results: Immunofluorescence staining showed the expression of VDR by primary Hodgkin’s (H) and Reed–Sternberg 
(RS)—HRS-tumor cells in HL histological sections. Western blot analyses revealed expression of VDR in the HL cell 
lines Hs445, HDLM2, KMH2, and L428. One-way analysis of variance (ANOVA) on data obtained from water-soluble 
tetrazolium 1 (WST-1) cell proliferation assay showed decreased cell growth in HDLM2 and L428, 72 h after treatment 
with 10 µM of either VD3 of VDAs. Western blot analyses showed that treatment of L428 cells with the VDAs (calcipo-
triol and EB1089) resulted in modest increases in nuclear accumulation of VDR (nuVDR) compared to either dimethyl 
sulfoxide (DMSO) or VD3 treatments. nuVDR for DMSO control and VD3 was comparable. These results suggest that 
VD3 or VDAs may affect growth of HL.
Keywords: Vitamin D3, Hodgkin’s lymphoma, Cancer, Oncology, Calcitriol, EB1089, Calcipotriol, B cell malignancy
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Vitamin D3 receptor signaling and its therapeutic per-
turbation with vitamin D3 (VD3, 1,25-dihydroxyvitamin, 
calcitriol) or vitamin D3 analogs (VDAs) have attracted 
much attention in cancer therapies, including treatment 
of B cell malignancies [1]. This is largely due to reports 
that showed strong association between VD3 deficiency 
and increased risk of both solid and liquid tumors [2–5]. 
In subsets of B cell malignancies, low vitamin D is asso-
ciated with worst prognosis—inferior event-free survival 
(EFS) and overall survival (OS) [2]. Studies showed that 
upon ligand (either VD3 or VDA) binding, VDR trans-
locates to the nucleus where it modulates the expression 
of genes involved in cell growth and differentiation and 
apoptosis [6].
Hodgkin’s lymphoma (HL) is presented as a unique 
B cell neoplasm characterized by the presence of giant 
mononuclear Hodgkin’s (H) and multinuclear Reed–
Sternberg (RS)—HRS-cells, which make up less than 1% 
of the cellular infiltrate of the tumor microenvironment. 
Although a previous immunohistochemical study showed 
that VDR is highly expressed in 80% of HL cases [7], very 
little is known about the influence of VD3/VDA–VDR 
interaction in this malignancy. Therefore, the goal of the 
current study was to investigate the effects of VD3/VDAs 




Immunofluorescence was performed as described by 
Gharbaran et al. [8] with some modifications. Tissue array 
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(US Biomax) consisting of 5-μm thick formaldehyde-
fixed paraffin-embed histological sections was dewaxed 
with 2× with xylene (10  min each), rehydrated in 100, 
80, 70, 50% ethanol (5 min each), and rinsed briefly in 1× 
PBS. Antigen retrieval was performed by heating sections 
for 20 min in 10 mM Na citrate (pH 6.0) at 95 °C followed 
by cooling for 20  min at room temperature. Sections 
were subsequently blocked with BSA (5% in Tris buffered 
saline (TBS, Sigma) then incubated overnight with anti-
VDR mouse monoclonal antibody (Santa cruz; sc-13133) 
diluted at 1:100 in blocking buffer, at 4  °C. The tissue 
array was next washed 3× in TBS for 5  min each. This 
was followed by incubation in Dylight 594-conjugated 
mouse secondary antibody (Jackson Immunoresearch) 
diluted at 1:500 in blocking buffer, in the dark for 1 h at 
room temperature, subsequent washes as described. The 
sections were covered with number 1 coverslips contain-
ing 10  µL of mounting medium containing DAPI (Vec-
tor Labs). Staining was visualized on a Nikon Ti Eclipse 
inverted microscope. Images were captured with a 
CoolSNAP HQ2 CCD camera (Photometric Scientific) 
coupled to the microscope and processed with Adobe 
Photoshop 7.0 (Adobe, San Jose, CA) for clarity. All steps 
were same for negative controls with the exception of 
incubation in primary antibody.
Cell lines and cell cultures
The human HRS-derived cell lines HDLM2, KMH2 and 
L428 were obtained from the German Collection of 
Microorganisms and Cell Cultures (DSMZ), Department 
of Human and Animal Cell Cultures, Braunschweig, 
Germany. Hs445 was obtained from the American Tis-
sue and Cell Collection (ATCC). L428 and KMH2 were 
cultured in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (Gibco BRL, 
Gaithersburg, MD), 1% l-glutamine, and penicillin/strep-
tomycin. Culture media for HDLM2 and Hs445 were 
similar but contained 20% heat-inactivated FBS. All cells 
were maintained in a humid environment of 5%  CO2 at 
37 °C.
Vitamin D3 and its chemical analogs
VD3 or VDAs (calcipotriol and EB1089) were purchased 
from Cayman Chemicals and dissolved in DMSO to pre-
pare a 10  mM stock which was aliquoted and stored at 
− 20 °C until ready to be used.
WST‑1 cell proliferation assay
2 × 105  cells/mL plated in 96-well plates overnight 
and treated with 10  μM each of VD3, calcipotriol, and 
EB1089 for 72 h were incubated in indicated culture con-
ditions. Cell growth was assessed with WST-1 cell prolif-
eration assay (Roche, USA), according to manufacturer’s 
instructions. In brief, 100 μL of treated cells were incu-
bated with 10  µL of WST-1 reagent for 3  h follow-
ing standard culture conditions. Absorbance was read 
at 450  nm on a Synergy H1 Hybrid microplate reader 
(BioTek). Cell growth (in percentages, %) was computed 
as ratio of absorbance (A450 nm) of treated cells relative 
to absorbance of control cells (DMSO) (A450 nm).
Preparation of nuclear extracts
L428 was plated at 1.5 × 105 cells/mL in 60-mm petri and 
incubated overnight. Cells were then treated with 10 μM 
each of VD3 or VDAs or vehicle (DMSO) and incu-
bated for another 48  h. Treated cells were harvested by 
centrifugation for 5 min at 300×g, then washed 2× with 
ice-cold 1× PBS. Cell membrane was lysed by resuspend-
ing the cells in 500 μL ice-cold hypotonic buffer (20 mM 
Tris–HCl, pH 7.4, 10  mM NaCl, 3  mM  MgCl2) supple-
mented with Halt Protease and Phosphatase Inhibitor 
Cocktail (Thermofisher) and incubated on ice for 15 min, 
with occasional mixing. The lysate was then mixed with 
25 μL of 10%  NP4O by vortexing for 10 s. The homoge-
nate was centrifuged at 3000  rpm for 10  min at 4  °C. 
Supernatant was transferred to a new tube and mix with 
RIPA (radioimmunoprecipitation) assay buffer (EMD 
Millipore) supplemented with protease and phosphatase 
inhibitor as described. Pellet (nuclear fraction) was resus-
pended in 150 μL ice-cold 1× RIPA buffer as described 
and incubated on ice, with vortexing at 10 min interval. 
Nuclear fraction was subsequently centrifuged for 30 min 
at 14,000×g at 4  °C and the supernatant aliquoted and 
stored at − 80  °C until ready for quantification by Brad-
ford assay and analysis by sodium dodysulfate polyacryla-
mide (SDS-PAGE) gel and Western blot.
Preparation of total cell extracts
Treated cells were collected and rinse as described, 
then resuspended in ice-cold RIPA buffer supplemented 
with Halt Protease and Phosphatase Inhibitor Cocktail 
(Thermo Scientific, Rockford, IL, USA). Lysates were 
incubated for 5 min on ice with periodic mixing followed 
by centrifugation at 13,000×g for 10 min at 4 °C. Super-
natant was transferred to new tube and stored at − 80 °C 
until ready for quantification by Bradford assay and SDS-
PAGE and Western blot analyses.
Western blot
Protein concentrations were determined using  Pierce® 
BCA Protein Assay kit (Thermo Scientific) following 
the manufacturer’s instructions. Twenty micrograms of 
protein were then loaded per well. Proteins were sepa-
rated on 10% SDS-PAGE and transferred to nitrocel-
lulose membrane (Odyssey 0.22  µm) using Bio-Rad 
Mini-PROTEAN Electrophoresis System. The membrane 
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was incubated overnight with the primary antibod-
ies at the indicated dilution prepared in TBST contain-
ing 2% BSA: anti-VDR (Santa Cruz; sc-13133, 1:1000), 
anti-histone (Invitrogen; 24HC2, 1:2000), anti-α-tubulin 
(Sigma; T6074, 1:2000). After brief rinses with TBST, the 
membrane was incubated with  IRDye® 680RD Donkey 
anti-Mouse (LI-COR, 926-68072), and  IRDye® 800CW 
Donkey anti-Rabbit (LI-COR, 926-32213) for 30  min. 
Membrane was finally rinsed as described and protein 
signal was imaged using Odyssey-CLX imaging system 
(Li-COR).
Statistical analyses
Data analyses were performed using SAS 9.1.3, StatView 
5, or JMP 4. Absorbance data reflection cell growth were 
presented as standard error of the mean (SEM) derived 
from triplicates. Analysis of variance (ANOVA) and F 
statistics were used to determine differences between 
the means as defined by p < 0.05. All experiments were 
repeated at least three times.
Results
Expression of VDR
The physiological responses of VD3/VDAs are mediated 
via VDR. Therefore, we analyze HL tissue sections and 
cell lines for the expression of VDR. Our immunofluo-
rescence staining showed the expression of VDR by HRS 
cells on tissue array (Fig. 1a). This observation is consist-
ent with a previous immunohistochemical study which 
showed that VDR is expressed by almost 80% of HL cases 
[7]. VDR expression by HL cell lines was determined by 
Western blot analyses. Hs445, HDLM2, KMH2, and L428 
showed relatively low expression but varying levels of 
VDR (Fig. 1b).
Effects of VD analogs on cell growth
Previous studies indicated growth-limiting activities of 
VD3/VDAs on both normal and malignant B lymphoid 
cells [9]. Therefore, we next studied the effects of VD3 
and the VDAs calcipotriol and EB1089 on the growth of 
HL cells HDLM2 and L428. One-way ANOVA on data 
obtained from WST-1 cell proliferation assay revealed 
decreases in growth of cells treated with either VD3 or 
VDAs, after 72  h (Fig.  2). As expected, EB1089 showed 
a greater effect in reducing growth of both HDLM2 and 
L428.
Nuclear accumulation
It has been suggested that upon ligand (VD3/VDAs) 
binding, VDR translocates to the nucleus where it 
a
b
Fig. 1 Detection of VDR expression in HL. a Tissue immunofluorescence staining showing the expression of VDR (red) in primary tumor cells of 
Hodgkin’s lymphoma, Hodgkin’s and Reed–Sternberg (HRS) cells. Nuclei of cells are stained with DAPI. Arrows indicate representative HRS cells. 
Scale bar = 100 μm. b Detection of VDR expression by Western blot in unstimulated HL cell lines. Arrow indicates VDR band. Histone was used as the 
house keeping protein
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modulates the expression of target genes. Therefore, we 
tested the effects of VD3/VDAs on the nuclear accu-
mulation of VDR by Western blot. L428 cells treated 
with 10  µM of VDAs for 48  h showed only a modest 
increase in nuVDR over either DMSO- or VD3-treated 
cells (DMSO and VD3 showed comparable effects on 
nuVDR)—Fig.  3. The modest changes in nuVDR in our 
study may be due to very low basal levels of VDR in 
unstimulated L428 cells.
Discussion
Our data showed that VDR is expressed by HL cell lines 
and primary HRS cells. The HL cell lines used in this 
study showed low but varying levels of VDR expression. 
Also, expression of VDR by HRS cells is qualitatively in 
accordance with the study by Renne et al. [7]. The results 
also showed that VD3/VDAs reduced growth of HL, 
in vitro, 72 h after treatment. The reduced cell growth of 
L428 was associated with modest increases in nuVDR in 
response to treatment with calcipotriol and EB1089.
In our study, the dose of VD3 (10  µM) used to elicit 
only modest decrease in cell growth is considered to be 
at supra-physiological concentration and this may be 
a consequence of low basal levels of VDR expression in 
unstimulated cells. In follicular low grade non-Hodgkin’s 
lymphoma (NHL), low levels of VDR expression was 
detected in primary tumor cells and cell lines (SU-DHL4 
and SU-DUL5), however high concentration of VD3 was 
used to produce growth restriction in vitro [10]. In con-
trast, cellular models of acute myeloid leukemia (HL-
60 cells) and diffuse large B cell lymphomas (DOHH2, 
K422) express high levels of VDR and display moderate 
cytotoxicity and pro-apoptotic responses upon exposure 
to nanomolar concentrations of VD3 (and VDAs) [11]. 
These observations suggest the levels of VDR expres-
sion in unstimulated cells may influence extent of VD3 
sensitivity of some B malignancies. Additionally, while 
VD3 fail to stimulate nuVDR in our study (compare to 
DMSO), nanomolar concentrations of VD3 resulted in 
significantly higher nuVDR in other B cell neoplasms 
[11].
Because low VDR expression may hinder anti-tumor 
activities of VD3, it will be important to develop strate-
gies to induce increased VDR expression. One of these 
approaches involved ligand-stimulated upregulation 
of receptor. It has been reported that VD3 stimulation 
resulted in the VDR upregulation [12, 13]. However, 
VD3-stimulated upregulation may not be possible in 
all types of VDR-positive neoplasms. Other approaches 
include the use of a non-vitamin inducer. Progester-
one directly induced upregulation of VDR expression 
in T lymphocytes, via binding progesterone receptor-
binding elements in the intron region after the first 
noncoding exon of the VDR gene [14]. In addition, pro-
gesterone enhanced the anti-tumor activities of VD3 by 
upregulating of VDR expression in endometrial cancer 



































DMSO VD3 Calcipotriol EB1089
Treatment
Fig. 2 Effects of VD3 and VDAs on growth of Hodgkin’s lymphoma. 
L428 and HDLM2 cells treated with 10 μM of either VD3 or VDAs 
(calcipotriol and EB1089) for 72 h showed modest decrease in 
growth. EB1089 showed the strongest effect
Fig. 3 Nuclear accumulation of VDR in L428 after treatment with 
VD3/VDAs for 48 h. EB1089 and calcipotriol resulted in greater nuVDR. 
DMSO and VD3 showed comparable levels of nuVDR. α-tubulin was 
used as the housekeeping protein
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be useful for cancer therapy in which primary tumor 
cells exhibit low levels of VDR expression.
Application of supra-physiological concentration of 
VD3 to suppress tumor growth in  vivo can promote 
hypercalcemia and hypercalciuria [16], leading to hard-
ening of soft tissues. As a result, low-calcemic VDAs 
were developed [11, 17]. Two of these molecules, cal-
cipotriol and EB1089 showed anti-tumor activities in a 
number of studies [18, 19]. However, EB1089 appeared 
to be amongst the most potent anti-tumor VDA [20]. In 
our study, treatment with either calcipotriol or EB1089 
resulted in significant decrease in cell growth which 
also correlated with greater nuVDR. Future studies are 
warranted to determine the underlying mechanism(s) 
by which calcipotriol and EB1089 limit growth of HL.
Limitations
Our study has limitations that must be considered. 
A positive control such as the breast cancer cell line 
MCF7 or the myeloid leukemia cell HL-60, both of 
which previously showed significant sensitivities to 
VD3/VDAs were not included in our study. The current 
study also suffers from a lack of cell cycle analysis and 
other molecular details.
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